Pfizer Inc. (PFE)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: price, fundamental, liquidity, and event gates pass, but technicalScore is 2/5 and there is no confirmed bullish setup. Price remains below SMA20/50/200 and EMA9/21, MACD is below signal and zero, and ADX 53.13 says the dominant trend is still down.
Company overview
Pfizer Inc. is a global biopharmaceutical company focused on the research, development, production, and distribution of a wide range of medicinal and vaccine products. Its portfolio includes treatments for cardiovascular and women's health, biologics, immunotherapies, and vaccines for infectious diseases. The company also engages in contract manufacturing and strategic collaborations with partners like Bristol-Myers Squibb and BioNTech.
Fundamental
fairPfizer's stable income and margins are offset by negative growth trends and regulatory risks.
Pfizer remains a profitable large-cap pharma with solid liquidity disclosed in its latest SEC 10-Q (cash ~$1.7B, short-term investments ~$11.4B, plus a $7B revolver; no going-concern/covenant flags). Valuation is fair-to-attractive (P/E ~18.66, EV/EBITDA ~12.14, FCF yield ~6.78%) and DCF estimates are above the current price, but leverage (net debt/EBITDA ~3.75) and negative 5-year growth from the post-COVID reset keep the overall setup mixed. FundamentalScore: 3.
Sentiment
fairSentiment is mixed, with recent FDA approval countered by negative trial news.
Near-term tape is mixed: FDA approval expanding IBRANCE use (regulator_confirmed, 2026-06-24) is supportive, but multiple primary outlets framed the Seagen-derived ADC (sigvotatug vedotin) Phase 3 NSCLC readout as a miss/disappointment (announced, 2026-06-22), keeping last ~14d media sentiment bearish and baseline delta indeterminate (baseline <3 usable articles). Red-Flag Screen: **moderate conflicting-catalyst-signal cap at 3**; no regulator-confirmed fraud/accounting investigation surfaced in the last 90d screen.
Technical
weakTechnical indicators show a strong downtrend with no confirmed bullish setup.
PFE is liquid and event-clean, but the daily chart remains a high-ADX downtrend; oversold readings support only a bounce attempt, not a confirmed 1–15 day bullish setup.
You’re looking at 2026-06-26 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.